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Abstract
Background: Polymorphisms in the interferon regulatory factor 5 (IRF5) gene are associated with susceptibility to
systemic lupus erythematosus, rheumatoid arthritis and other diseases through independent risk and protective
haplotypes. Several functional polymorphisms are already known, but they do not account for the protective
haplotypes that are tagged by the minor allele of rs729302.
Methods: Polymorphisms in linkage disequilibrium (LD) with rs729302 or particularly associated with IRF5
expression were selected for functional screening, which involved electrophoretic mobility shift assays (EMSAs) and
reporter gene assays.
Results: A total of 54 single-nucleotide polymorphisms in the 5’ region of IRF5 were genotyped. Twenty-four of
them were selected for functional screening because of their high LD with rs729302 or protective haplotypes. In
addition, two polymorphisms were selected for their prominent association with IRF5 expression. Seven of these
twenty-six polymorphisms showed reproducible allele differences in EMSA. The seven were subsequently analyzed
in gene reporter assays, and three of them showed significant differences between their two alleles: rs729302,
rs13245639 and rs11269962. Haplotypes including the cis-regulatory polymorphisms correlated very well with IRF5
mRNA expression in an analysis based on previous data.
Conclusion: We have found that three polymorphisms in LD with the protective haplotypes of IRF5 have
differential allele effects in EMSA and in reporter gene assays. Identification of these cis-regulatory polymorphisms
will allow more accurate analysis of transcriptional regulation of IRF5 expression, more powerful genetic association
studies and deeper insight into the role of IRF5 in disease susceptibility.
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Introduction
The interferon regulatory factor 5 (IRF5) gene occupies a
prominent place among the genetic factors involved in
susceptibility to rheumatic and autoimmune diseases [1].
It is associated with a large series of diseases, either defini-
tively, as with systemic lupus erythematosus (SLE) [2-7],
Sjögren’s syndrome, systemic sclerosis, primary biliary cir-
rhosis and rheumatoid arthritis; or more tentatively, as
with granulomatosis with vasculitis, multiple sclerosis,
inflammatory bowel disease and atherosclerosis [1].
Discovery of these associations has contributed to
increased interest in the role of type I interferon in auto-
immune diseases and to progress in understanding of dis-
ease pathogenesis, particularly regarding SLE [8,9].
However, advances could be made faster if we understood
the molecular and cellular mechanisms involved. A variety
of functional polymorphisms have already been identified
in the IRF5 locus, but their relationship with disease sus-
ceptibility is still unclear.
Four polymorphisms with a putative functional role
have been described [2-4,7,10,11]. The first identified is
rs2004640, in which the T allele introduces a donor
splice site for alternative first exons [3]. However, its
in vivo relevance has been questioned [7]. Another,
rs10954213, creates an early polyadenylation site that
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leads to shorter IRF5 mRNA isoforms with longer half-
lives [4]. This single-nucleotide polymorphism (SNP) has
the strongest evidence for a role in cis-regulatory element
of IRF5 [12,13]. The remaining two functional poly-
morphisms are of the insertion-deletion (indel) type. One
of them, with 3x or 4x copies of CGGGG in the IRF5
promoter, affects transcription levels by differential bind-
ing of the specificity protein 1 (Sp1) transcription factor
[10,11]. The other changes 10 amino acids encoded in
exon 6, but experimental evidence of any effect of this
change in the IRF5 protein is still lacking [7].
Various models have been proposed to account for the
association with disease in this locus, including combi-
nations of the functional polymorphisms [4-7,11], but
none is completely satisfactory. In particular, haplotypes
with two opposed effects have consistently been
observed in the association of IRF5 with SLE [4-7] and
with other diseases [14-17]. However, we still do not
know the causes of the two effects. Most studies have
focused on the risk haplotype (designated as haplotype 6
in [5,12,15] and described in Additional file 1: Note S1),
which has a frequency of about 10% in controls and
nearly 20% in SLE patients. This haplotype includes
alleles that determine increased expression of the gene
(the 4x allele of the CGGGG indel in the promoter) and
longer half-life of the mRNA (the A allele of rs10954213
in the 3’ untranslated region). However, it is unclear
whether increased expression is the only mechanism
involved, because there are other haplotypes that include
combinations of the same alleles but are not associated
with increased SLE risk (for example, haplotypes 4 and
5, which include alleles 4x and A but are neutral). It has
been proposed that the difference between the risk and
the neutral haplotypes resides in interactions with other
functional polymorphisms, such as the indel in exon 6,
but this hypothesis lacks experimental support. Less
effort has been put into investigating the protective effect
of IRF5 variants. In multiple studies, disease protection is
associated with the minor allele of rs729302 [4-6], which
is a SNP of unapparent functionality located 5’ to the
gene, and with two haplotypes (designated as haplotypes
1 and 2 in our studies; see Additional file 1: Note S1).
This protective effect does not correlate with the known
functional polymorphisms. Therefore, we currently lack
any explanation for disease protection to account for cis
polymorphisms in the IRF5 locus.
Our aim in the present study has been to identify new
functional polymorphisms that could contribute to the
protective effect of IRF5 haplotypes. Given the location
of rs729302 and its linkage disequilibrium (LD) pattern,
our focus has been to study polymorphisms 5’ to IRF5
and in its first intron that could affect transcription
through differential binding of nuclear proteins. Our
exploration followed an experimental process (Figure 1)
initiated by selecting polymorphisms based on tight LD
with rs729302 or the protective haplotypes as well as on
the basis of their prominent association with IRF5 tran-
scription levels. This approach led to the selection of 26
polymorphisms for functional screening. First screening
was done by searching allele differential patterns in elec-
trophoretic mobility shift assays (EMSAs) with B cell
line nuclear extracts. Seven polymorphisms showed dif-
ferential binding in these assays and were brought to
luciferase reporter gene assays. Three of the seven poly-
morphisms showed differential luciferase expression
with their two alleles. These three new cis-regulatory
polymorphisms, rs729302, rs13245639 and rs11269962,
will allow more accurate understanding of IRF5 tran-
scriptional variation and its role in disease susceptibility,
as suggested already by our preliminary analysis of their
haplotype assignments.
Materials and methods
Genotypes, linkage disequilibrium map and haplotype
analysis
The region extending from chr7:128,343,695-128,393,203
of the Human March 2006 genome assembly (NCBI36/
hg18) that includes the coding sequence of IRF5, 21.5 kb
of its promoter region (from the start of exon 1, variant A)
and part of the transportin 3 (TNPO3) locus, which is 3’ to
IRF5, was screened for polymorphisms. Only tag SNPs
were selected in about half of this region; in the promoter
and first intron of IRF5, however, we selected all SNPs
characterized by double-hits in NCBI dbSNP Build 128
[18]. The 54 selected SNPs (Additional file 2: Table S1)
were analyzed in DNA samples obtained from peripheral
blood mononuclear cells (PBMCs) of 95 Spanish healthy
controls recruited in our center. They provided their writ-
ten informed consent to participate in the study, and the
study was approved by the Ethics Committee for Clinical
Research of Galicia. Genotypes were obtained by single-
base extension with the SNaPshot Multiplex Kit (Applied
Biosystems, Carlsbad, CA, USA) as described previously
[5], except for rs3778752, rs3778751 and the CGGGG
indel, which were sequenced; the exon 6 indel, which was
genotyped by length variation in agarose gel electrophor-
esis as described previously [5]; and rs10954213, which
was genotyped using a fluorogenic 5’ nuclease assay (Taq-
Man MBG Probes, TaqMan SNP Genotyping Assay;
Applied Biosystems). The primers and probes used are
given in Additional file 2: Table S2. The genotyping call
rate was 97.7%. All the SNPs were in Hardy-Weinberg
equilibrium with a threshold for significance of 0.05 with-
out correction for multiple testing. Pairwise D’ values, r2
values and their graphic representation were obtained
using Haploview software at the default settings [19].
Haplotypes were estimated using PHASE 2.1 software (at
default parameters), which implements a very accurate
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Bayesian algorithm [20]. Two haplotype distribution ana-
lyses were done, the first to select SNPs for functional
studies, including all SNPs of potential interest and the
second to put the new functional polymorphisms in con-
text, including only the functional and tag SNPs. Func-
tional screening was conducted on three additional
polymorphisms selected on the basis of their relationship
with IRF5 expression or their known cis-regulatory effect.
This information is detailed in Additional file 2: Table S3.
Cell culture and nuclear extracts
The B-lymphocyte cell line WIL2 NS [21,22], which con-
stitutively expresses IRF5 (Additional file 3: Figure S1),
was obtained from the European Collection of Cell Cul-
tures (catalogue no. 90112121). It was maintained in
RMPI 1640 medium supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 1 U/ml penicillin and
0.1 mg/ml streptomycin. For the preparation of nuclear
extracts, 107 cells were washed in 1 ml of phosphate-
buffered saline and incubated at 4°C for 15 min with
200 μl of a lysis buffer containing 10 mM 2-[4-(2-hydro-
xyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), pH
7.9, 1 mM ethylenediaminetetraacetic acid (EDTA),
1 mM ethylene glycol tetraacetic acid, 10 mM KCl,
1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl
fluoride, 10 μg/ml aprotinin and 10 μg/ml of leupeptin.
The freed nuclei were incubated at 4°C for 30 min with
0.1% Triton X-100 and collected by centrifugation at
800 × g during 15 min at 4°C. Subsequently, they were
incubated at 4°C for 30 min with rotation in 200 μl of
the previously specified lysis buffer supplemented with
20% glycerol and 0.4 M KCl. Insoluble material was
Figure 1 Experimental design of the search for new functional polymorphisms in IRF5. Polymorphisms for functional screening were
selected on the basis of correlation with systemic lupus erythematosus (SLE) protection or prominent role is IRF5 cis-regulation models. A first
functional screen by electrophoretic mobility shift assay (EMSA) was applied to the 26 selected polymorphisms, and a second screen with
reporter gene assays was applied to the 7 polymorphisms with differential EMSA results. *More single-nucleotide polymorphisms (SNPs) were
possible, but they had already been selected in previous groups to the right. RNA-seq = RNA sequencing.
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precipitated by centrifugation for 15 min at 13,000 rpm
and 4°C. All the mentioned reagents were obtained
from Sigma-Aldrich (St Louis, MO, USA). Nuclear pro-
teins in the supernatant were quantified using the Quant-
iT Protein Assay Kit (Molecular Probes, Eugene, OR,
USA) in a Qubit fluorometer (Invitrogen, Carlsbad, CA,
USA). Quantified nuclear extracts were stored at -80°C
until use.
Electrophoretic mobility shift assay
Oligonucleotides for each allele and strand centered in
the 25 selected polymorphisms plus the CGGGG indel
used as a positive control were synthesized by Sigma-
Genosys (Haverhill, UK) (Additional file 2: Table S4).
Complementary oligonucleotides were annealed at 37°C
for 1 h to form the double-stranded probes used in
EMSA. The LightShift Chemiluminescent EMSA Kit
(Pierce Biotechnology, Rockford, IL, USA) was used
with some modifications. Briefly, the binding reaction
was performed with 0.5 nM of double-stranded, biotin-
labeled oligonucleotides and 0.5 to 4.0 μg of nuclear
extract proteins from WIL2 NS cells. This reaction was
brought to a final volume of 20 μl with binding buffer
(10 mM Tris·HCl, pH 7.5, 10 mM KCl, 0.6 mM DTT,
50 ng/μl poly(deoxyinosinic-deoxycytidylic) acid,
1.5 mM EDTA, 2 mM HEPES, pH 7.9, 25 mM NaCl,
0.1 mM ZnSO4, 15% glycerol and 0.25 mg/ml bovine
serum albumin) and incubated at room temperature for
20 min. Cold competition was done with a 200-fold
molar excess (0.1 μM) of the unlabeled oligonucleotide.
DNA-protein complexes were analyzed by electrophor-
esis in 5% polyacrylamide nondenaturing gels and 0.5 ×
Tris/borate/EDTA buffer at 11 V/cm and 4°C for 3 h.
Subsequently, they were transferred to nylon membranes
according to a semidry transfer protocol for 45 min at
12 V. The complexes were cross-linked to the nylon mem-
brane with ultraviolet (UV) light at 7.2 J/cm2. Detection
was done with the LightShift Chemiluminescent EMSA
Detection Module (Pierce Biotechnology) followed by
exposure to UV light using the UVP EC3 Imaging System
(UVP, Upland, CA, USA). A minimum of three indepen-
dent replicate experiments were done for each EMSA
showing differential binding.
Luciferase reporter assays
Fourteen different constructs were made, one for each
of the alleles of the seven polymorphisms with differen-
tial EMSA results. The IRF5 sequence (148 to 245 bp in
length) of each of these polymorphisms was obtained
from heterozygous subjects by polymerase chain reac-
tion (PCR) with the same primers used for genotyping
(Additional file 2: Table S5). None of them included
additional polymorphisms. The amplicons were first
inserted into the EcoRV site of a pBlueScript (pBK SK-)
vector by TA cloning. Briefly, the EcoRV cut vector was
treated with Taq DNA polymerase in the presence of
2 mM deoxythymidine triphosphate and PCR buffer, and
50 μg of this 3’ T-vector were ligated to 25 μg of the PCR
amplicon in a 10-μl reaction with 1 μl of T4 DNA ligase
reaction buffer (New England Biolabs, Ipswich, MA, USA)
and 1× ligase buffer at 16°C overnight. The cloned IRF5
sequences were subcloned into the KpnI/SmaI sites of a
fos-pGL3-basic vector, which are just upstream of the
minimal fos promoter regulating expression of the Firefly
luciferase gene. The sequence and orientation of each
insert were verified by DNA sequencing. These verified
reporter vectors were transfected in WIL2 NS cells. Speci-
fically, each experiment included five conditions: blank,
positive control, empty vector, allele 1 and allele 2. The
experiments were carried out by transfecting 2 × 106
WIL2 NS cells with 400 ng of the adenovirus E1 region
RSV-Luc vector plus 2,800 ng of the pBK SK- vector for
the positive control, 3,200 ng of the fos-pGL3 basic vector
for the empty vector, 3,200 ng of the allele 1 fos-pGL3 vec-
tor construct, and 3,200 ng of the allele 2 fos-pGL3 vector
construct for each of the two alleles. All transfections also
included 800 ng of the pRL-TK Renilla luciferase vector
(Promega, Madison, WI, USA) for normalization. Trans-
fections were done by microporation in 100 μl of Resus-
pension Buffer R at 1,100 V for 30 ms and a single-pulse
program in the Neon Transfection System (Invitrogen).
After microporation, the transfected cells were left in cul-
ture for 24 h (basal) or left for 20 h. The luciferase activity
was measured using the Firefly Luciferase and the Renilla
Luciferase Assay systems (both from Promega). The
results for Firefly luciferase were expressed as relative luci-
ferase units after normalization with the Renilla luciferase
activity and with the empty vector for the respective
experiments. At least five independent experiments were
performed for each of the seven analyzed polymorphisms.
Comparison of the log-transformed mean normalized
Firefly luciferase luminescence ratios was done using the
Wilcoxon matched-pairs test.
Results
Selection of promoter polymorphisms on the basis of
linkage disequilibrium and haplotypes
The experimental design involved selection of SNPs on
the basis of three criteria (Figure 1): high r2 values with
rs729302, high correlation with the protective haplo-
types and prominent association with IRF5 expression.
These three criteria are not mutually exclusive, and
many SNPs were selected for more than one of them.
The selected SNPs were evaluated for their effect in
binding nuclear proteins as an indication of their possi-
ble role in cis-regulation of IRF5 expression by means of
EMSA. The SNPs with differential binding to their
alleles in EMSA were assessed with reporter gene assays,
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and those showing changes in expression between the
constructs with the two alleles were considered to be
functional (Figure 1).
To identify SNPs strongly correlated with rs729302 or
with the protective haplotypes, we genotyped 54 poly-
morphisms located predominantly within 21.5 kb of the 5’
region of IRF5 (Additional file 2: Table S1) in 95 Spanish
controls. The D’ and r2 pairwise values were calculated for
44 polymorphisms (Additional file 2: Table S6), which
excluded eight SNPs with minor allele frequencies less
than 2% (rs12536195, rs6951615, rs11773414, rs11983607,
rs11763323, rs754280, rs41298401 and rs11767834) and
two SNPs that were completely redundant with rs3778753
(rs3778752 and rs3778751). This analysis showed a block
of LD extending over 43 kb from TPNO3 to the 5’ region
of IRF5 further from the gene than rs729302 (Figure 2A).
This block included 37 of the analyzed SNPs. A second
block of LD with seven SNPs was even further 5’ to IRF5
than the first. In the largest block of LD, there were two
areas of stronger correlation between SNPs (Figure 3B),
one of them (8 kb) included rs729302 and other eight
SNPs (r2 ≥ 0.7 with rs729302). These nine SNPs were
selected for functional screening (Table 1). The pattern of
LD was very similar in the 379 samples of European
ancestry in phase 1 of the 1000 Genomes project (Addi-
tional file 3: Figure S2) [23].
Next, we studied the haplotypes of the 37 SNPs in the
large LD block. There were 20 haplotypes with frequen-
cies over 1% that represented 85.3% of the chromo-
somes in the studied samples (Table 2). Thirteen of the
twenty common haplotypes could be traced back as sub-
haplotypes of the six haplotypes defined with tag SNPs
in our previous studies (and described in Additional file
1: Note S1) [5,12,15]. The other seven haplotypes were
new. On the basis of these data, we selected for func-
tional analysis the 15 SNPs with minor alleles in the
haplotypes that generally (>50%) carried the minor allele
of rs729302 (Table 2).
Selection of polymorphisms on the basis of their
association with IRF5 expression
A recent analysis by our group, in which we combined
data from multiple microarray experiments in lymphoblas-
toid cell lines, highlighted four IRF5 polymorphisms in the
best models accounting for IRF5 expression [12]. We
selected three of them for the current study. One of them
is the CGGGG indel, which is already known to influence
IRF5 expression [10,11]. It was selected as a sort of posi-
tive control (Table 1). The second is rs3807306, which had
already been selected on the basis of our haplotype analy-
sis. The third is rs17424179, which was not included in
our LD analysis because it is 68 kb 3’ to IRF5 and we
selected it at this stage. The fourth SNP in the microarray-
derived model, rs10954213, was not selected because it is
in the IRF5 coding sequence and affects mRNA stability.
We selected an additional polymorphism on the basis
of IRF5 expression data obtained using the RNA-seq
approach (E Alonso-Perez, unpublished data). More
details are available in Additional file 1: Note S2. Briefly,
the transcriptome of the 60 cell lines of the HapMap
CEPH (Utah residents with ancestry from northern and
western Europe: CEU) collection was obtained from a
published study [24]. After alignment of the RNA-derived
sequences, reads corresponding to exons were counted
together with the junction reads, and the total was nor-
malized and used as a measure of the expression level.
This measure for each cell line was used as the variable
to explain the genotypes of 264 IRF5 polymorphisms
from the 1000 Genomes project. The most significantly
associated polymorphism in this analysis was rs11269962
(P = 0.002), which is a 14-bp indel placed 2.2 kb
upstream of the IRF5 gene (Table 1).
Screening of functional polymorphisms with
electrophoretic mobility shift assay
We considered it likely that the SNPs of interest could
have a functional effect dependent on the differential
allele binding of nuclear proteins. EMSA was used as a
screening tool for these differences. We used nuclear
extracts from a lymphoblastoid cell line in basal condi-
tions. A total of 26 polymorphisms were subjected to
this screening (Figure 1): 9 in the rs729302 high-correla-
tion group, 15 from the haplotype selection and 2 on
the basis of their association with IRF5 expression
(Table 1). In addition, we analyzed the CGGGG indel as
a positive control (Additional file 3: Figure S3A).
Only 7 of the 26 polymorphism showed differential
allele patterns in EMSA. The first was rs729302 itself,
which showed additional binding with the C allele rela-
tive to the A allele (Figure 3A). Two others were from
the group in tight LD with rs729302. The minor G allele
of rs12706860 showed a specific pattern of additional
bands with delayed migration when it was compared
with the major C allele (Figure 3B). The other SNP of
this group, rs13245639, showed specific band slowdown
with its minor T allele in comparison with the major C
allele (Figure 3C). Also, two of the SNPs selected on the
basis of IRF5 protective haplotypes, rs3778754 and
rs3807307, showed differential EMSA results. The G
allele of rs3778754 showed delayed bands that were
much more prominent with the C allele than with the G
allele (Figure 3D). Interpretation of this difference was
complicated by the lack of specificity of the G allele
band, which was attenuated by competition with
the unlabelled oligonucleotide but not completely
suppressed. In spite of this lack of specificity, other
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differences between EMSAs with the two alleles led us to
select this SNP for further study. The next SNP,
rs3807307, showed an additional and specific band shift
with the major C allele that migrated faster than the
band that was common to the two alleles (Figure 3E).
The two polymorphisms selected on the basis of their
Figure 2 IRF5 linkage disequilibrium maps. Pairwise D’ (A) and r2 (B) between 44 polymorphisms in the IRF5 locus obtained in 95 Spanish
healthy controls are represented. Ten additional single-nucleotide polymorphisms (SNPs) were excluded because of low minor allele frequency
(<2%) or complete redundancy with other SNPs (see Results). Color scale from white to red indicates D’ values from 0 to 1 in (A) and that from
white to black indicates r2 values from 0 to 1 in (B). The triangle in (B) surrounds the block containing SNPs in tight linkage disequilibrium with
rs729302. Positions of the coding sequences of IRF5 and TNPO3 are signaled.
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prominent association with IRF5 expression also showed
differential EMSA results. For rs17424179, there were two
shifted bands with the two alleles; however, the slowest
band was much more intense than the fastest one with the
G allele, and this difference was not as marked for the A
allele (Figure 3F). For the major allele of rs11269962, the
14-bp insertion, a specific delayed band was observed that
was absent with its minor allele (Figure 3G).
These differential patterns of binding with nuclear
extracts of the B cell line WIL2 NS were obtained in three
or more concordant experiments. None of the other 19
analyzed polymorphisms showed differential results in
EMSA. Among them was rs4728142, which has been
reported to show differential allele intensity of the delayed
band [25]. We analyzed this SNP with particular attention,
but we did not detect any difference between the two
alleles (Additional file 3: Figure S4).
Luciferase gene reporter assays
To further assess the functionality of the seven poly-
morphisms that had shown differential EMSA results
(Table 1), we performed luciferase gene reporter assays.
Each polymorphism was tested with a pair of vectors: one
for each allele (148 to 245 bp in length; see Additional
file 2: Table S5). They did not contain any other SNP.
Inserts for the seven polymorphisms plus those used as
positive controls (CGGGG indel) were introduced
upstream of the fos minimal promoter in fos-pGL3 vec-
tors. These constructs were transiently transfected into
the B-lymphocyte cell line WIL2 NS. The CGGGG indel
showed higher expression with the 4x allele than with the
3x allele (Wilcoxon test; P = 0.043), as described pre-
viously [11] (Additional file 3: Figure S3B).
Three of the seven newly studied polymorphisms
showed differential luciferase expression: (1) rs729302
Figure 3 Seven IRF5 polymorphisms showing differential electrophoretic mobility shift assay results. Seven of the twenty-six
polymorphisms analyzed by electrophoretic mobility shift assay (EMSA) showed differential patterns of delayed migration with their two alleles.
(A) rs729302. (B) rs12706860. (C) rs13245639. (D) rs3778754. (E) rs3807307. (F) rs17424179. (G) rs11269962. They were analyzed with WIL2 NS cell
nuclear extracts, and the specificity of the bands was checked by competition with unlabeled oligonucleotides in 200-fold excess. Each
difference was established in three independent EMSAs with concordant results. Sequences of the probes are given in Additional file 2: Table S4.
Alonso-Perez et al. Arthritis Research & Therapy 2013, 15:R82
http://arthritis-research.com/content/15/4/R82
Page 7 of 14
itself (Figure 4A), (2) rs13245639 (Figure 4C), both from
the group of SNPs in tight LD with rs729302, and (3)
the 14-bp indel rs11269962 (Figure 4G). The minor C
allele of rs729302 showed increased expression relative to
the major A allele, but the difference was only borderline
(Figure 4A). Constructs with the major C allele of
rs13245639 showed a significant increase in luciferase
expression compared with the minor T allele (Figure 4C).
The construct with the 14-bp indel of rs11269962 showed
a significant decrease in luciferase expression relative to
the construct with the deletion allele (Figure 4G). These
latter results were consistent with the RNA-seq analysis,
which showed higher expression with the deletion allele.
The remaining four SNPs with differential EMSA results
did not show significant differences in the reporter gene
assays (Figures 4B, D, E and 4F).
Haplotype assignments of the new functional
polymorphisms
We performed an estimation of haplotypes to facilitate
interpretation of the newly identified functional
polymorphisms. The three new functional polymorph-
isms, comprising the two known cis-regulatory poly-
morphisms (CGGGG indel and rs10954213) and the
eight tag SNPs used in our previous studies (total of
thirteen polymorphisms), were included in this analysis.
In this way, it was possible to explore retrospectively
correspondences between the functional polymorphisms
and IRF5 mRNA expression or association with SLE, as
observed in previous studies [5,12]. We obtained nine
haplotypes of relative high frequency that accounted for
83.2% of the total (Table 3). They included the six pre-
viously studied (described in Additional file 1: Note S1)
and three new ones, which were excluded from further
analysis because of lack of information. The remaining
six haplotypes still accounted for 74.2% of the total,
allowing for meaningful analysis. We computed a sum
score of the alleles of the five functional polymorphisms
assigned to each haplotype in function of the increased
(H) or decreased (L) regulation associated with them
(Table 3). These sum scores were correlated with the
corresponding IRF5 expression or association with SLE.
Table 1 Polymorphisms in the IRF5 locus screened by functional tests.a
Polymorphism Position Gene Alleles MAF Selection criteriab EMSA Reporter
rs4731530 128562578 5’ IRF5 C > T 39.9 Hap -
rs6950728 128565661 5’ IRF5 G > A 30.9 r2 = 0.97 -
rs11982901 128566754 5’ IRF5 C > T 31.6 r2 = 0.97 -
rs4728141 128567032 5’ IRF5 C > T 49.5 Hap -
rs13245639 128567810 5’ IRF5 C > T 31.6 r2 = 0.97 + +
rs729302 128568960 5’ IRF5 A > C 31.1 r2 = 1.0 -
rs729068 128569561 5’ IRF5 C > T 31.1 r2 = 0.9 -
rs12706860 128570026 5’ IRF5 C > G 33.7 r2 = 0.83 + +
rs7808659 128570238 5’ IRF5 C > A 30.4 r2 = 0.9 -
rs754284 128571478 5’ IRF5 C > G 31.6 r2 = 0.87 -
rs4728142 128573967 5’ IRF5 G > A 47.8 Hap -
rs7801838 128573994 5’ IRF5 C > T 28.9 r2 = 0.73 -
rs3778754 128575552 5’ IRF5 G > C 48.9 Hap + -
rs11269962 128575812 5’ IRF5 ins > del 48.9 RNA-seq + +
rs3757388 128576023 5’ IRF5 A > G 33.3 Hap -
rs3757387 128576086 5’ IRF5 T > C 49.4 Hap -
rs3757385 128577304 5’ IRF5 G > T 33.3 Hap -
rs3807135 128577617 5’ IRF5 C > T 33.0 Hap -
CGGGG indel 128577931 5’ IRF5 del > ins 48.4 Known cis-eQTL + +
rs3807307 128579202 IRF5 C > T 47.8 Hap + -
rs3823536 128579666 IRF5 A > G 47.8 Hap -
rs3778753 128580042 IRF5 G > A 47.8 Hap -
rs3778752 128580047 IRF5 T > G 47.8 Hap -
rs3778751 128580048 IRF5 T > A 47.8 Hap -
rs3807306 128580680 IRF5 T > G 45.7 Hap/microarray -
rs17424179 128657995 TPNO3 G > A 3.8c Microarray + -
aThe polymorphisms’ genomic position, relation to genes, alleles, minor allele frequency (MAF), criteria of selection and results of the electrophoretic mobility
shift assay (EMSA) and reporter gene assays are shown. bSelection criteria were hap = concordance of the minor allele with the minor allele of rs729302 in most
haplotypes; r2 = level of genotype correlation with rs729302; RNA-seq = polymorphism most associated with RNA-seq data; microarray = specially associated
single-nucleotide polymorphisms in microarray expression analysis. cFrequency from HapMap (Hap) CEPH (Utah residents with ancestry from northern and
western Europe: CEU) individuals. eQTL = expression quantitative trait loci.
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For expression, we used the weighted means of the hap-
lotype-specific regression coefficients in four microarray
experiments with lymphoblastoid cell lines [12]. Correla-
tion between the expression levels and the sum score of
the cis-regulatory polymorphisms was very good (rs =
0.93, P = 0.008). In contrast, correlation of these sum
scores with the effect size (odds ratio) of each haplotype
in SLE association [5] was high but not significant (rs =
0.74, P = 0.09).
Discussion
We have identified three new functional polymorphisms in
the 5’ region of IRF5 that contribute to the complex sce-
nario of cis-regulation of this gene. These polymorphisms
have been identified by concordant results in EMSA and
gene reporter assays with a B cell line, which is a relevant
cell type for SLE pathogenesis. Therefore, it is likely that
the three polymorphisms affect IRF5 levels by the differen-
tial binding of transcription factors or other regulatory
proteins. Their identification opens new possibilities for
research to obtain a more accurate understanding of IRF5
transcriptional variation between subjects, as well as the
identification of transcription factors with critical in vivo
roles. In addition, this type of knowledge will allow refined
understanding of the participation of IRF5 in disease sus-
ceptibility. First evidence of the future possibilities was
obtained with the retrospective analysis of the assigned
haplotype associations with IRF5 expression and SLE
susceptibility.
Identification of the three new functional polymorph-
isms was based on differences in EMSA and reporter gene
assays. All these assays have been replicated, and therefore
we are confident in the results. However, these assays and
their interpretation can be problematic in some situations.
For example, there were two EMSAs with difficult inter-
pretation: for rs3778754 due to lack of specificity of a
band and for rs1742417 because only differences in inten-
sity were found. In these two cases, reporter gene assays
were negative, allowing us to concentrate on the most
consistent results. Further confidence in the positive find-
ings could be gained from studying additional cell lines.
We did not check other cells, but one of the newly identi-
fied functional SNPs, the 14-bp indel rs11269962, is in a
region identified as a strong enhancer in another lympho-
blastoid cell line (GM12878) by the Encyclopedia of DNA
Elements (ENCODE) Consortium’s ENCODE project [26],
which has analyzed the whole genome for regulatory
sequences.

















































































































































4 24.7 C G C C C A C C C A T G A C G C T C C A G T A A T G T T T
4 1.1 - - - - - - - - - - - - - - - - - - - - - G - - - - - - -
4 3.2 T - - - - - - - - - - - - - - - - - - - - - - - - - - - -
na 1.6 - - - - - - - - - - - - - - - - - - T - - - - - - - - - -
5 3.2 - - - - - - - - - - - - - - - - - - - - - - - - - A - - -
6 6.8 - - - - - - - - - - - - - - - - - - - - - - G - - A C - C
6 2.6 - - - - - - - - - G - - - - - - - - - - - - G - - A C - C
na 1.6 - - - - T - - - - G - - - T - - - - T - - - - - - A - - -
na 1.6 T - - - T C - - - - - - - - - - - - - - - - - - - - - - -
na 2.6 - - - - T - - - - G - C - T - - - T - G A G G G A A - - C
na 1.1 - - - - T - - - - G - C - T - - - T T G A G G G A A - - C
3 7.9 T A G G T - T T T G C C G T T T G T T G A G G G A A - C C
3 1.1 T A G G T - T - - G - C G T T T G T T G A G G G A A - C C
3 2.6 T - - - - - T T T G C C G T T T G T T G A G G G A A - C C
2 7.9 T - - - T C - - - G - C G T T T G T T G A G G G A A - C C
2 1.1 T - - - T C - - - G - C G T T T G T T G A G G G A A - C C
2 3.2 - - - - T C - - - G - C G T T T G T T G A G G G A A - C C
1 5.3 T - - - T C - - - G - C - T - - G T - G A G - - - A - - -
na 3.2 - - - - T C - - - G - C - T - - G T - G A G - - - - - - -
na 3.2 T - - - T C - - - G - C G T T T G T T G A - - - - - - - -
aDashes represent the same allele as the uppermost sequence. Minor alleles >50% concordant with the C allele of rs729302 are in bold, and the name of the
polymorphism is also in bold. IRF5 tag single-nucleotide polymorphisms (SNPs) are in italics. The eight SNPs with high correlation with rs729302 are not
represented. bHaplotype numbers are as previously described. na = not applicable for lack of correspondence. cThree completely redundant SNPs
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We used sensitive techniques, both in EMSA and in the
reporter gene assay. In this respect, the use of a weak
promoter in the reporter gene assays, as well as the use
of normalization of transfection efficiency with the
cotransfected Renilla luciferase signal, is of particular
relevance. In addition to these general procedures, we
analyzed EMSA for rs4728142 with special attention,
given the previously reported differences [25], but we
found no differences. Our results do not exclude other
IRF5 cis-regulatory polymorphisms in response to stimuli
or those specific to other cell types, but cell-specific regu-
latory polymorphisms are a small minority [27,28]. Also,
our study did not address specific effects of IRF5 alterna-
tive splicing isoforms and avoided expression data from
exons with multiple isoforms, such as exon 1. In addition,
it did not address many other polymorphisms in the
locus. In addition, the known differences in IRF5 haplo-
types, as well as their SLE association and cis-regulation
between Europeans, Asians and Africans [29-32], do not
allow extension of our findings to other ethnic groups
without studying them (Additional file 1: Note S1). In
spite of this caution, we noted that the functional SNP
rs13245639 showed r2 values over 0.94 with rs729302 in
East Asian and African samples from phase 1 of the 1000
Figure 4 Reporter gene assays of the seven IRF5 polymorphisms with differential electrophoretic mobility shift assays. Each graph
represents the geometric mean and the 95% confidence interval of ratios between the luciferase signals of the WIL2 NS cells transfected with
the two alleles of (A) rs729302, (B) rs12706860, (C) rs13245639, (D) rs3778754, (E) rs3707307, (F) rs17424179 and (G) rs11269962. The dotted
horizontal line corresponds to a ratio of 1.0 or identical expression with the two alleles. *P < 0.05 by Wilcoxon matched-pairs test of five
independent experiments, except for rs12706860, for which seven experiments were done.
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Genomes project [23]. This result suggests that
rs13245639 could play a similar role in SLE susceptibility
in these ethnic groups. In contrast, the third functional
SNP, rs11269962, showed r2 = 0.36 with rs729302 in our
samples and below 0.05 in both Asians and Africans.
The three new cis-regulatory polymorphisms complete
the two that were already known. This number of cis-
regulatory polymorphisms is large but not surprising.
A high number is consistent with the findings of experi-
ments looking for IRF5 expression quantitative trait loci
in lymphoblastoid cell lines [33-36]. These studies found
that most SNPs in IRF5 were associated with its mRNA
levels. This result cannot be explained with one or two
cis-regulatory SNPs. Also, previous analyses have shown
that the best models accounting for variation in IRF5
expression require combinations of several cis-regulatory
SNPs [12]. In addition, multiple functional cis-regulatory
polymorphisms in the same gene have already been
found in loci associated with other complex diseases
[37-39]. The complex structure of gene regulation that
has been uncovered in recent years, involving multiple
molecular interactions, specifically the binding with
DNA of multiple transcription factors [40], makes it
likely that this type of finding will become more com-
mon with progress in the identification of causal
polymorphisms.
A limitation of our study is that it did not assess the dis-
ease significance of the findings in patients and controls.
However, it should be noted that this type of analysis has
many difficulties. The number of cis-regulatory poly-
morphisms and the presence of LD between them makes
it very difficult to discern their specific contributions in
epidemiological or ex vivo studies. Only a small fraction of
the many possible combinations of cis-regulatory poly-
morphisms are present in the population at a significant
frequency. Therefore, the observable expression levels
do not allow the distinction of individual effects of each
polymorphism. In this way, the in vivo relevance of the
cis-regulatory polymorphisms is only inferred, because it is
very difficult to replicate the results demonstrated in
in vitro analysis. These difficulties have already been
encountered in previous studies that failed to replicate the
IRF5 in vitro results in studies done in PBMCs from SLE
patients and healthy controls [13,41]. These analyses will
be much more difficult to perform with the addition of the
three functional SNPs described herein that show LD
between them and with the CGGGG indel (as shown in
the haplotype analysis in Table 3). An alternative will be to
demonstrate that the polymorphisms are in transcription
factor-binding sites (TFBSs) that are functional in vivo and
that these TFBSs are disrupted by one of the two alleles.
These experiments can be done ex vivo with cells taken
from patients or healthy controls using techniques such as
chromatin immunoprecipitation [42]. To do these ana-
lyses, we need to identify the relevant transcription factors.
Our repeated attempts were unsuccessful (data not
shown). They were based on supershift assays with specific
antibodies against the most likely transcription factors
according to the known TFBSs. These negative results are
not surprising, because detection of TFBSs with available
bioinformatics tools is notoriously inefficient [43]. How-
ever, we plan to pursue the search by taking advantage of
a new approach based on proteomic analysis [39] that is
more accurate, although very complex to set up.
The phenotypes in cells or in patients are the sum of
the functional alleles present. Therefore, the relevant
units of ascertainment of the expression levels are the
haplotypes containing the various functional polymorph-
isms, which we have applied in our current study. For
this analysis, we took advantage of previously defined
haplotypes and their association with IRF5 expression
and with SLE susceptibility. Correlation of the sum
Table 3 Assignment of cis-regulatory polymorphisms to haplotypes with associated mRNA expression and systemic
lupus erythematosus susceptibility.a
Haplotypeb % Alleles at haplotypec Allele effectd Expression Association
1 5.3 TCIDGCATATTT LHLLH 0.24 (-0.3 to 0.8) 0.75 (0.6 to 0.9)
2 14.2 TCIDGTGAATCC LHLLL -1.10 (-1.5 to -0.7) 0.79 (0.7 to 0.9)
3 13.7 CAIDGTGAATCC HLLLL -1.33 (-1.7 to -1.0) 0.89 (0.8 to 1.1)
4 29.5 CADITCATGTTT HLHHH 0.84 (0.5 to 1.2) 0.95 (0.8 to 1.1)
5 2.6 CADITCATATTT HLHHH 1.63 (0.7 to 2.6) 1.06 (0.8 to 1.4)




aFive cis-regulatory polymorphisms and seven tag SNPs are represented. Allele effects to increased (H) or decreased (L) expression are signaled. Combinations of
these effects were retrospectively correlated with the mean specific expression in unstimulated lymphoblastoid cells (95% C.I.)[12] and OR (95% C.I.) of the
association with SLE[5]. bHaplotype numbers as previously described. na = not applicable for lack of correspondence. cOrder of polymorphisms is: rs13245639,
rs729302, rs11269962, CGGGG indel, rs2004640, rs752637, rs10954213, rs13242262, rs10488630, rs10488631, rs2280714 and rs4731535. dOrder of allele effects:
rs13245639, rs729302, rs11269962, CGGGG indel and rs10954213.
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scores of cis-regulatory polymorphisms in each haplotype
with IRF5 expression in lymphoblastoid cells was very
good. This result is only preliminary, but it is promising.
We expect that direct assessment of haplotypes defined by
the functional polymorphisms will be even more corre-
lated with the expression levels. It is also likely that the
modest correlation of the sum scores observed in our cur-
rent study will improve in case-control association studies
that include all the functional polymorphisms. However, it
has already been signaled that SLE’s association with IRF5
is unlikely to be fully explained by cis-regulatory poly-
morphisms [12,41]. Other changes in IRF5 function
beyond mRNA expression levels seem to be needed.
Conclusions
We have identified three new functional cis-regulatory
IRF5 polymorphisms. Together with the two that were
already known, they correlate very well with previously
defined haplotype effects on IRF5 expression. Knowledge
of these IRF5 functional polymorphisms will increase the
power of association and expression quantitative trait loci
studies because power is always greater for causal poly-
morphisms than for markers in imperfect LD with them.
They will also increase our capacity to understand the role
of IRF5 in disease pathogenesis.
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